Pharsight

Emend patents expiration

EMEND's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214692 MERCK Medical use for tachykinin antagonists
Sep, 2012

(11 years ago)

US5538982 MERCK Medical use for tachykinin antagonists
Jul, 2013

(10 years ago)

US5719147 MERCK Morpholine and thiomorpholine tachykinin receptor antagonists
Apr, 2015

(9 years ago)

US6096742 MERCK Polymorphic form of a tachykinin receptor antagonist
Jul, 2018

(5 years ago)

US8258132 MERCK Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(3 years from now)

Emend is owned by Merck.

Emend contains Aprepitant.

Emend has a total of 5 drug patents out of which 4 drug patents have expired.

Expired drug patents of Emend are:

  • US7214692
  • US5538982
  • US5719147
  • US6096742

Emend was authorised for market use on 30 June, 2006.

Emend is available in capsule;oral dosage forms.

Emend can be used as prevention of postoperative nausea and vomiting, treatment or prevention of emesis.

The generics of Emend are possible to be released after 26 September, 2027.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 28, 2018
M(M-82) Mar 19, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 30 June, 2006

Treatment: Treatment or prevention of emesis; Prevention of postoperative nausea and vomiting

Dosage: CAPSULE;ORAL

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214692 MERCK AND CO INC Medical use for tachykinin antagonists
Sep, 2012

(11 years ago)

US5538982 MERCK AND CO INC Medical use for tachykinin antagonists
Jul, 2013

(10 years ago)

US5512570 MERCK AND CO INC Treatment of emesis with morpholine tachykinin receptor antagonists
Mar, 2014

(10 years ago)

US5716942 MERCK AND CO INC Treatment of migraine with morpholine tachykinin receptor antagonists
Feb, 2015

(9 years ago)

US5691336 MERCK AND CO INC Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
Mar, 2019

(5 years ago)

US5691336

(Pediatric)

MERCK AND CO INC Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
Sep, 2019

(4 years ago)

Emend is owned by Merck And Co Inc.

Emend contains Fosaprepitant Dimeglumine.

Emend has a total of 6 drug patents out of which 6 drug patents have expired.

Expired drug patents of Emend are:

  • US7214692
  • US5538982
  • US5512570
  • US5716942
  • US5691336
  • US5691336*PED

Emend was authorised for market use on 25 January, 2008.

Emend is available in powder;intravenous dosage forms.

Emend can be used as prevention or treatment of nausea or emesis induced by a cancer chemotherapeutic agent.

Drug patent challenges can be filed against Emend from 03 October, 2020.

The generics of Emend are possible to be released after 02 May, 2025.

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-186) May 02, 2025
New Dosing Schedule(D-155) Feb 01, 2019
New Patient Population(NPP) Apr 03, 2021
Pediatric Exclusivity(PED) Oct 03, 2021
New Chemical Entity Exclusivity(NCE) Jan 25, 2013
New Dosing Schedule(D-128) Nov 12, 2013

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using FOSAPREPITANT DIMEGLUMINE ingredient

NCE-1 date: 03 October, 2020

Market Authorisation Date: 25 January, 2008

Treatment: Prevention or treatment of nausea or emesis induced by a cancer chemotherapeutic agent

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents
EMEND's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6096742 MSD MERCK CO Polymorphic form of a tachykinin receptor antagonist
Jul, 2018

(5 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(3 years from now)

Emend is owned by Msd Merck Co.

Emend contains Aprepitant.

Emend has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Emend are:

  • US6096742

Emend was authorised for market use on 17 December, 2015.

Emend is available in for suspension;oral dosage forms.

Emend can be used as prevention of nausea and vomiting associated with chemotherapy (cinv).

The generics of Emend are possible to be released after 26 September, 2027.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Aug 28, 2018

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of EMEND before it's drug patent expiration?
More Information on Dosage

EMEND family patents

Family Patents